Grant Number:	1R01CA165609-01A1 Interpret this number
Primary Investigator:	Schulz, Richard
Organization:	University Of South Carolina At Columbia
Project Title:	Southern Oncology Network on Adverse Reactions (SONAR) - Focus on Tyrosine Kinase
Fiscal Year:	2012

DESCRIPTION (provided by applicant): Assessments of barriers to dissemination of serious adverse drug reaction (sADR) information are important for patient safety. Timely information dissemination on sADRs is important for oncology drugs, as they are toxic to normal and malignant cells, have high sADR rates, and often receive accelerated approval and/or priority review. Recently, the Food and Drug Administration (FDA) has approved tyrosine kinase inhibitors (TKIs), an important novel drug class administered for chronic mylogenous leukemia, gastrointestinal stromal tumors, renal cell cancers, and hepatocellular carcinoma. One concern is that drugs that receive accelerated approval or priority review are associated with sADRs not reported in a timely manner. Our objective is to develop the Southern Oncology Network on Adverse Reactions (SONAR) to evaluate sADRs for TKIs and DECREASE the duration of time between sADR identification and FDA/sponsor actions. The work builds on our identification of 50 sADRs, our sub-award from ERG assisting FDA's Center for Drug Evaluation and Research, our collaboration with former Connecticut Attorney General Richard Blumenthal that decreased the time-lag between thalidomide-sADR identification and sponsor/FDA safety-actions by several years, and FDA interest in TKI-associated cardiotoxicity. Our prior work, supported by five R01s, led to major publications, "Black Box" warnings, "Dear Doctor" letters, and changes in use of block-buster pharmaceuticals (e.g. erythropoietin/darbepoetin). Our aims are to: identify, evaluate, and report case information for TKI-associated cardiotoxicity and other sADRs; identify factors associated with shorter time periods for identification/dissemination of sADR information; develop a novel approach to streamlining sADR information dissemination (building on our successful pilot effort); and participate in a FDA initiative that will link molecular toxic target studies (basic science) and organ-level toxicity (clinical science), with TKI-associated cardiotoxicity being the first area of study. We will disseminate brief reports for 25 to 50 TKI-associated sADRs and "Citizen's Petitions" to the FDA for sADRS for which our consultants identify as candidates for "Black Box" warnings or "Dear Doctor" letters (translating research into policy). The second component will be hypothesis driven, identifying factors associated with delayed sADR identification/reporting. The proposed innovative study will be the first to systematically attempt to shorten the six to seven year time lag between identification and reporting of oncology drug- associated sADRs and the first collaboration that provides information for FDA-led investigation of biologic and clinical aspects of a sADR involving an entire drug class. PUBLIC HEALTH RELEVANCE: The Study of Oncology-related Adverse Reactions (SONAR) project will identify, evaluate, and report important safety information for a novel class of anti-cancer agents, tyrosine kinase inhibitors. Also, as part of hypothesis testing research, the project seeks to identify factors associated with delayed identification of serious adverse drug reactions associated with these agents as well as delays in dissemination of the relevant safety information to the medical community. As such, this will be the first study to systematically evaluate factors associated with delays in identification and reporting of serious adverse drug reactions associated with cancer agents.




Concerns regarding "GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes".
Authors: Weng C.H. , Bennett C.L. , Magagnoli J. , Chou C.C. , Chan P.A. .
Source: Diabetes, Obesity & Metabolism, 2025-11-14 00:00:00.0; , .
EPub date: 2025-11-14 00:00:00.0.
PMID: 41236181
Related Citations

Post-Marketing Safety Assessment for Glucagon-Like Peptide-1 and Dual Incretin Therapies in Diabetes and Obesity.
Authors: Weng C.H. , Bennett C.L. , Magagnoli J. , Richardson C. .
Source: Journal Of Clinical Pharmacology, 2025-10-10 00:00:00.0; , .
EPub date: 2025-10-10 00:00:00.0.
PMID: 41074403
Related Citations

Comment on: Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study.
Authors: Weng C.H. , Chan P.A. , Magagnoli J. , Bennett C.L. .
Source: Drug Safety, 2025-09-26 00:00:00.0; , .
EPub date: 2025-09-26 00:00:00.0.
PMID: 41003919
Related Citations

Mitigating the Impact of Drug Shortages in Oncology: Lessons Learned From the 2023 Shortages of Carboplatin and Cisplatin.
Authors: Izen M.L. , McKoy J.M. , Martin L. , Nabhan C. , Watson G.L. , Magagnoli J. , Carson K.R. , Knopf K. , Smith E. , Zyszkowski E. , et al. .
Source: Cancer Journal (sudbury, Mass.), 2025 Sep-Oct 01; 31(5), .
EPub date: 2025-09-25 00:00:00.0.
PMID: 41002874
Related Citations

Cancer Drugs and United States Tariffs: Attention Must Be Paid.
Authors: Izen M.L. , McKoy J.M. , Martin L. , Nabhan C. , Watson G.L. , Magagnoli J. , Carson K.R. , Knopf K. , Smith E. , Zyszkowski E. , et al. .
Source: Cancer Journal (sudbury, Mass.), 2025 Sep-Oct 01; 31(5), .
EPub date: 2025-09-25 00:00:00.0.
PMID: 41002875
Related Citations

Congressional Investigation of RevAssist-Linked and General Pricing Strategies for Lenalidomide.
Authors: Bennett C.L. , Gibbons J.B. , Trujillo A. , Carson K.R. , Knopf K. , Nabhan C. , Rosen S.T. , Aboulafia D.M. .
Source: Jco Oncology Practice, 2024 Aug; 20(8), p. 1021-1026.
EPub date: 2024-02-27 00:00:00.0.
PMID: 38412398
Related Citations

Addressing the Drug-Shortage Crisis in Oncology.
Authors: Yang Y.T. , Socal M. , Bennett C.L. .
Source: Jama Oncology, 2024-02-01 00:00:00.0; 10(2), p. 155-156.
PMID: 38175651
Related Citations

United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism.
Authors: Bennett C.L. , Georgantopoulos P. , Gale R.P. , Knopf K. , Hrushesky W.J. , Nabhan C. , Armitage J.O. .
Source: Expert Opinion On Drug Safety, 2023 Jul-Dec; 22(9), p. 783-788.
EPub date: 2023-08-18 00:00:00.0.
PMID: 37594915
Related Citations

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Authors: Bennett C.L. , Schoen M.W. , Hoque S. , Witherspoon B.J. , Aboulafia D.M. , Hwang C.S. , Ray P. , Yarnold P.R. , Chen B.K. , Schooley B. , et al. .
Source: The Lancet. Oncology, 2020 Dec; 21(12), p. e575-e588.
PMID: 33271114
Related Citations

Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development.
Authors: Ambati J. , Magagnoli J. , Leung H. , Wang S.B. , Andrews C.A. , Fu D. , Pandey A. , Sahu S. , Narendran S. , Hirahara S. , et al. .
Source: Nature Communications, 2020-09-23 00:00:00.0; 11(1), p. 4737.
EPub date: 2020-09-23 00:00:00.0.
PMID: 32968070
Related Citations

Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et al.
Authors: Bennett A.C. , Bennett C.L. , Witherspoon B.J. .
Source: Expert Opinion On Drug Safety, 2020 08; 19(8), p. 1057-1058.
PMID: 32364807
Related Citations

Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.
Authors: Smalls D.J. , Kiger R.E. , Norris L.B. , Bennett C.L. , Love B.L. .
Source: Pharmacotherapy, 2019 Dec; 39(12), p. 1190-1203.
EPub date: 2019-11-03 00:00:00.0.
PMID: 31596963
Related Citations

An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.
Authors: Bennett A.C. , Bennett C.L. , Witherspoon B.J. , Knopf K.B. .
Source: Expert Opinion On Drug Safety, 2019 Nov; 18(11), p. 1055-1063.
EPub date: 2019-09-18 00:00:00.0.
PMID: 31500468
Related Citations

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
Authors: Georgantopoulos P. , Yang H. , Norris L.B. , Bennett C.L. .
Source: Cancer Medicine, 2019-04-14 00:00:00.0; , .
EPub date: 2019-04-14 00:00:00.0.
PMID: 30983123
Related Citations

Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
Authors: Chen B.K. , Yang Y.T. , Bennett C.L. .
Source: Drugs, 2018-11-16 00:00:00.0; , .
EPub date: 2018-11-16 00:00:00.0.
PMID: 30446980
Related Citations

Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Authors: Bennett C.L. , Berger J.R. , Sartor O. , Carson K.R. , Hrushesky W.J. , Georgantopoulos P. , Raisch D.W. , Norris L.B. , Armitage J.O. .
Source: British Journal Of Haematology, 2018 01; 180(2), p. 301-304.
EPub date: 2016-09-21 00:00:00.0.
PMID: 27649938
Related Citations

Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions.
Authors: Yoshii Y. , Fujimura Y. , Bennett C.L. , Isonishi A. , Kurumatani N. , Matsumoto M. .
Source: Transfusion, 2017 08; 57(8), p. 2045-2053.
EPub date: 2017-05-12 00:00:00.0.
PMID: 28500622
Related Citations

Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
Authors: Bian J. , Chen B. , Hershman D.L. , Marks N. , Norris L. , Schulz R. , Bennett C.L. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2017-06-10 00:00:00.0; 35(17), p. 1945-1951.
EPub date: 2017-04-25 00:00:00.0.
PMID: 28441110
Related Citations

Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
Authors: Noxon V. , Knopf K.B. , Norris L.B. , Chen B. , Yang Y.T. , Qureshi Z.P. , Hrushesky W. , Lebby A.A. , Schooley B. , Hikmet N. , et al. .
Source: Journal Of Oncology Practice, 2017 06; 13(6), p. e562-e573.
EPub date: 2017-05-15 00:00:00.0.
PMID: 28504901
Related Citations

The mechanisms of sudden-onset type adverse reactions to oseltamivir.
Authors: Hama R. , Bennett C.L. .
Source: Acta Neurologica Scandinavica, 2017 Feb; 135(2), p. 148-160.
PMID: 27364959
Related Citations

Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
Authors: Yang Y.T. , Chen B. , Bennett C.L. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2016-12-20 00:00:00.0; 34(36), p. 4320-4322.
EPub date: 2016-10-31 00:00:00.0.
PMID: 27998222
Related Citations

Peginesatide For The Treatment Of Anemia Due To Chronic Kidney Disease - An Unfulfilled Promise
Authors: Hermanson T. , Bennett C.L. , Macdougall I.C. .
Source: Expert Opinion On Drug Safety, 2016 Oct; 15(10), p. 1421-6.
PMID: 27551882
Related Citations

Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
Authors: Raisch D.W. , Rafi J.A. , Chen C. , Bennett C.L. .
Source: Expert Opinion On Drug Safety, 2016 Aug; 15(8), p. 1003-11.
PMID: 27268272
Related Citations

Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry.
Authors: Magwood-Golston J.S. , Kessler S. , Bennett C.L. .
Source: Leukemia Research, 2016 May; 44, p. 61-4.
PMID: 27030962
Related Citations

FDA Approval of Extended-Release Oxycodone for Children With Severe Pain.
Authors: Yang Y.T. , Chen B. , Bennett C.L. .
Source: Pediatrics, 2016 05; 137(5), .
EPub date: 2016-04-19 00:00:00.0.
PMID: 27244829
Related Citations

Relationship of Industry Sponsorship to Results of Cost-Effectiveness Analyses of Drugs Used in Breast Cancer Treatment--Reply.
Authors: Bennett C.L. , Lane J.D. .
Source: Jama Oncology, 2016 Apr; 2(4), p. 549.
PMID: 27077903
Related Citations

Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.
Authors: Riches M.L. , Trifilio S. , Chen M. , Ahn K.W. , Langston A. , Lazarus H.M. , Marks D.I. , Martino R. , Maziarz R.T. , Papanicolou G.A. , et al. .
Source: Bone Marrow Transplantation, 2016 Feb; 51(2), p. 277-82.
PMID: 26524262
Related Citations

Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
Authors: Lane J.D. , Friedberg M.W. , Bennett C.L. .
Source: Jama Oncology, 2016 Feb; 2(2), p. 274-6.
PMID: 26658959
Related Citations

Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network.
Authors: Kaur K. , Fayad R. , Saxena A. , Frizzell N. , Chanda A. , Das S. , Chatterjee S. , Hegde S. , Baliga M.S. , Ponemone V. , et al. .
Source: The Journal Of Community And Supportive Oncology, 2016 Feb; 14(2), p. 54-65.
PMID: 26955658
Related Citations

Petitioning the FDA to Improve Pharmaceutical, Device and Public Health Safety by Ordinary Citizens: A Descriptive Analysis.
Authors: Chen B.K. , Yang Y.T. , Cheng X. , Bian J. , Bennett C.L. .
Source: Plos One, 2016; 11(5), p. e0155259.
PMID: 27171162
Related Citations

Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor.
Authors: Hermanson T.T. , Hrushesky W.J. , Knopf K.B. , Bennett C.L. .
Source: Journal Of Oncology Practice / American Society Of Clinical Oncology, 2015 Sep; 11(5), p. 363-4.
PMID: 26243648
Related Citations

High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?
Authors: Mahal B.A. , Chen M.H. , Bennett C.L. , Kattan M.W. , Sartor O. , Stein K. , D'Amico A.V. , Nguyen P.L. .
Source: Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / Esmo, 2015 Jul; 26(7), p. 1390-5.
PMID: 25926039
Related Citations

Editorial Comment.
Authors: Chen R. , Terris M.K. .
Source: Urology, 2015 Jun; 85(6), p. 1434.
PMID: 25872700
Related Citations

Population-Based Assessment of Determining Treatments for Prostate Cancer.
Authors: Prasad S.M. , Sartor A.O. , Bennett C.L. .
Source: Jama Oncology, 2015 Apr; 1(1), p. 67-8.
PMID: 26182306
Related Citations

The association between race and treatment regret among men with recurrent prostate cancer.
Authors: Mahal B.A. , Chen M.H. , Bennett C.L. , Kattan M.W. , Sartor O. , Stein K. , D'Amico A.V. , Nguyen P.L. .
Source: Prostate Cancer And Prostatic Diseases, 2015 Mar; 18(1), p. 38-42.
PMID: 25348256
Related Citations

Japanese regulatory authority's perspective on biosimilars - authors' reply.
Authors: Bennett C.L. , Chen B. , Hermanson T. , Georgantopoulos P. , Sartor O.A. .
Source: The Lancet. Oncology, 2015 Mar; 16(3), p. e102.
PMID: 25752553
Related Citations

Cardiac risks associated with antibiotics: azithromycin and levofloxacin.
Authors: Lu Z.K. , Yuan J. , Li M. , Sutton S.S. , Rao G.A. , Jacob S. , Bennett C.L. .
Source: Expert Opinion On Drug Safety, 2015 Feb; 14(2), p. 295-303.
PMID: 25494485
Related Citations

Editorial Comment
Authors: Sartor O. , Bennett C.L. .
Source: Urology, 2015 Jan; 85(1), p. 153-4.
PMID: 25530377
Related Citations

Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab.
Authors: Bennett C.L. , Newsome S.D. , Sartor O. , Carson K.R. .
Source: Cancer, 2014-12-15 00:00:00.0; 120(24), p. 4006-7.
EPub date: 2014-12-15 00:00:00.0.
PMID: 25123754
Related Citations

Regulatory and clinical considerations for biosimilar oncology drugs.
Authors: Bennett C.L. , Chen B. , Hermanson T. , Wyatt M.D. , Schulz R.M. , Georgantopoulos P. , Kessler S. , Raisch D.W. , Qureshi Z.P. , Lu Z.K. , et al. .
Source: The Lancet. Oncology, 2014 Dec; 15(13), p. e594-605.
PMID: 25456378
Related Citations

Editorial Comment
Authors: Hermanson T. , Sartor O. , Ablin R.J. , Bennett C.L. .
Source: Urology, 2014 Nov; 84(5), p. 1072.
PMID: 25443906
Related Citations

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.
Authors: Carson K.R. , Newsome S.D. , Kim E.J. , Wagner-Johnston N.D. , von Geldern G. , Moskowitz C.H. , Moskowitz A.J. , Rook A.H. , Jalan P. , Loren A.W. , et al. .
Source: Cancer, 2014-08-15 00:00:00.0; 120(16), p. 2464-71.
EPub date: 2014-08-15 00:00:00.0.
PMID: 24771533
Related Citations

Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers.
Authors: Bennett C.L. , Bian J. .
Source: British Journal Of Cancer, 2014-07-29 00:00:00.0; 111(3), p. 421-3.
PMID: 25072302
Related Citations

Anaphylaxis and hypotension after administration of peginesatide.
Authors: Bennett C.L. , Jacob S. , Hymes J. , Usvyat L.A. , Maddux F.W. .
Source: The New England Journal Of Medicine, 2014-05-22 00:00:00.0; 370(21), p. 2055-6.
PMID: 24849101
Related Citations

Emerging drugs for treatment of anemia of chronic kidney disease.
Authors: Magwood J.S. , Lebby A. , Chen B. , Kessler S. , Norris L. , Bennett C.L. .
Source: Expert Opinion On Emerging Drugs, 2013 Dec; 18(4), p. 421-9.
PMID: 24033253
Related Citations

Can Patients Afford to Be Adherent to Expensive Oral Cancer Drugs?: Unintended Consequences of Pharmaceutical Development.
Authors: Felder T.M. , Bennett C.L. .
Source: Journal Of Oncology Practice, 2013 Nov; 9(6S), p. 64s-66s.
PMID: 29431040
Related Citations

Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.
Authors: Strassels S.A. , Dickson M. , Norris L.B. , Bennett C.L. .
Source: Journal Of The National Cancer Institute, 2013-08-07 00:00:00.0; 105(15), p. 1072-3.
EPub date: 2013-08-07 00:00:00.0.
PMID: 23873406
Related Citations

Rituximab and biosimilars - equivalence and reciprocity.
Authors: Qureshi Z.P. , Magwood J.S. , Singh S. , Bennett C.L. .
Source: Biosimilars, 2013-06-14 00:00:00.0; 2013(3), p. 19-25.
PMID: 24829884
Related Citations

Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).
Authors: Bennett C.L. , Jacob S. , Dunn B.L. , Georgantopoulos P. , Zheng X.L. , Kwaan H.C. , McKoy J.M. , Magwood J.S. , Qureshi Z.P. , Bandarenko N. , et al. .
Source: British Journal Of Haematology, 2013 Jun; 161(6), p. 896-8.
PMID: 23530950
Related Citations

Colony-stimulating factors for febrile neutropenia during cancer therapy.
Authors: Bennett C.L. , Djulbegovic B. , Norris L.B. , Armitage J.O. .
Source: The New England Journal Of Medicine, 2013-03-21 00:00:00.0; 368(12), p. 1131-9.
PMID: 23514290
Related Citations